Satellite Symposium at the
26th European Congress of Pathology
Pathologists’ role in CD30 detection:
the first steps toward optimal treatment of haematological malignancies
31 August 2014 13:00–14:30
ExCeL, London, United Kingdom
Capital Suite 8/11

Peter Borchmann

Germany

Peter Borchmann is Assistant Medical Director in the Department of Haematology and Oncology at the University Hospital of Cologne, Germany. He is also Secretary of the German Hodgkin’s Lymphoma Study Group (GHSG).

Professor Borchmann received his medical degree in 1995 from the University of Cologne, where he has remained for the rest of his career to date. From 1995 to 2000 he worked in the 1st Department of Internal Medicine, where he participated in the design of clinical studies, and was sub-investigator in several haemato-oncological clinical trials.

From 2000 to 2001 he was a member of the scientific working group at the Laboratory for Immunotherapy, working on design and production of recombinant bispecific molecules for the treatment of Hodgkin lymphoma (Hl).

Since 2010, he has been Professor of Internal Medicine and has been responsible for the design and execution of several phase 1, 2, and 3 clinical trials, concentrating on malignant lymphomas and acute and chronic leukaemia.

Professor Borchmann’s scientific focus is on the development of new treatments in HL, as well as in preclinical and clinical investigations. Within the GHSG, he is leader of the working group “Survivorship” and is responsible for the development of clinical studies for advanced-stage patients.

Chair:

Wolfram Klapper
Germany
Faculty:

Peter Borchmann
Germany

Laurence de Leval
Switzerland

Pier Paolo Piccaluga
Italy
This meeting is an
Excerpta Medica activity.
logos
Support for this educational activity is provided by
Takeda Oncology.
logos